Repligen Corporation to Present at Upcoming Investor Conferences

Rhea-AI Summary

Repligen Corporation (NASDAQ:RGEN) will be presenting at two upcoming investor conferences: William Blair’s 43rd Annual Growth Stock Conference in Chicago on June 8, 2023, and Jefferies’ Global Healthcare Conference in New York on June 8, 2023. The presentations will provide company overviews by Tony J. Hunt, President and CEO, and Jon K. Snodgres, CFO, respectively. The webcast of the presentations will be accessible through Repligen’s Investor Relations website.

Positive

• Repligen Corporation will be presenting at two upcoming investor conferences, which could positively impact the stock price. The conferences include William Blair’s 43rd Annual Growth Stock Conference in Chicago on June 8, 2023, and Jefferies’ Global Healthcare Conference in New York on June 8, 2023. The presentations will provide valuable insights into the company's operations and future prospects.

Negative

• None.

WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences.

• William Blair’s 43^rd Annual Growth Stock Conference being held in Chicago June 6-8. Tony J. Hunt, President and Chief Executive Officer, is scheduled to present a company overview on June 8, 2023 at 11:20 a.m. CT.
• Jefferies’ Global Healthcare Conference being held in New York June 7-9. Jon K. Snodgres, Chief Financial Officer, is scheduled to present a company overview on June 8, 2023 at 1:30 p.m. ET.

A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at http://www.repligen.com. Follow us on LinkedIn and Twitter.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com 

FAQ

When and where are the upcoming investor conferences that Repligen Corporation will be presenting at?

Repligen Corporation will be presenting at William Blair’s 43rd Annual Growth Stock Conference in Chicago on June 8, 2023, and Jefferies’ Global Healthcare Conference in New York on June 8, 2023.

Who will be presenting at the conferences?

Tony J. Hunt, President and CEO, will present at William Blair’s 43rd Annual Growth Stock Conference, and Jon K. Snodgres, CFO, will present at Jefferies’ Global Healthcare Conference.

Will the presentations be available online?

Yes, the presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com.

Will there be a replay of the presentations available?

Yes, the webcast of the presentations will be available for replay for a limited period of time following the events.